State Street 13F: Adds $7.3M to ARWR Stake
State Street raised its holdings in Arrowhead Pharmaceuticals by over 92,000 shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
State Street added 92,300 shares to its stake in Arrowhead Pharmaceuticals, Inc. ($ARWR), a 1.44% increase, according to a 13F filing with the SEC dated May 15, 2026. It reported 6,496,130 shares worth $512.48 million at the end of the quarter.
Since the filing, $ARWR is down 2.2% after 1 week, up 0.6% after 1 month and down 27.1% to date (from the $76.67 close on May 15, 2026).
ARWR
Arrowhead Pharmaceuticals, Inc.
Key Points
- State Street boosted its position in Arrowhead Pharmaceuticals by 92,300 shares, bringing its total to 6,496,130 shares worth $526.4 million.
- Arrowhead Pharmaceuticals, trading at $81.04, has a market cap of about $11.4 billion and a 52-week high of $82.48.
- Recent insider transactions include buys by COO Patrick O'Brien and sales by Chief Medical Officer James Hamilton.
Get $ARWR trade alerts by text
We text you when insiders, Congress or big funds trade $ARWR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Arrowhead Pharmaceuticals, Inc. alert may contain errors. Disclosures
State Street has increased its holdings in Arrowhead Pharmaceuticals, Inc. (NasdaqGS: ARWR), adding 92,300 shares. This brings its total stake to 6,496,130 shares, valued at approximately $526.4 million, according to the latest Form 13F filing with the SEC as of May 15, 2026.
What Changed in State Street's Arrowhead Pharmaceuticals Position
State Street's recent move saw an increase of 92,300 shares in Arrowhead Pharmaceuticals, representing a 1.44% uptick from its previous holding of 6,403,830 shares. The value of the new position is reported at $526.4 million, indicating a continued interest in the biotechnology firm.
Other Institutional Activity in Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals has seen varied activity from other institutional investors as well. BlackRock, Inc. reduced its stake by 3,157,063 shares, holding 18,161,519 shares worth about $1.14 billion. Avoro Capital Advisors LLC increased its position by 74,999 shares, leading to a total of 10,699,999 shares valued at approximately $670.9 million. FMR LLC boosted its holdings by 746,244 shares, ending with 7,266,652 shares valued at $455.6 million. Vanguard Portfolio Management LLC now holds 7,146,136 shares worth about $448.1 million, while Vanguard Capital Management LLC holds 6,032,416 shares valued at $378.2 million.
Arrowhead Pharmaceuticals, Inc. Stock Up 18.7%
Shares of Arrowhead Pharmaceuticals recently traded at $81.04. The company has a market capitalization of around $11.4 billion. Its forward P/E ratio is not meaningful as the company is not currently profitable. Arrowhead has a beta of 1.275, indicating some volatility compared to the market. The stock's 52-week range is between $14.30 and $82.48, with a 50-day moving average of $73.79 and a 200-day moving average of $57.84.
Recent Earnings
Arrowhead Pharmaceuticals reported revenue of $622 million, though it saw a revenue decline of 86.4%. The company has a net margin of -48.38% and a return on equity of -42.37%. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Arrowhead Pharmaceuticals, Inc.
Recent insider activity includes several transactions. On June 15, 2026, Matthew Gregory Cohen acquired 11,882 shares. On May 12, 2026, Hongbo Lu sold 2,970 shares at $76.88 as part of a planned sale. James Hamilton, the Chief Medical Officer, sold 10,000 shares at $75.00 on April 23, 2026, also as part of a planned sale. Chief Financial Officer Daniel Joseph Apel sold 13,095 shares at $71.35 on April 22, 2026, under a planned sale.
Analysts Set New Price Targets
Several analysts have recently updated their price targets for Arrowhead Pharmaceuticals. On June 17, 2026, Leerink Partners maintained a hold rating with a $72.00 target. Bernstein also maintained a hold rating with a $46.00 target on May 13, 2026. RBC Capital maintained a buy rating with an $87.00 target on May 8, 2026. JP Morgan initiated coverage with a buy rating and an $88.00 target on May 1, 2026. The consensus recommendation is a buy, with an average target price of $88.17 based on 12 analyst opinions.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. is a biotechnology company based in Pasadena, California. It develops medicines aimed at treating challenging diseases. The company is involved in several clinical trials, including efforts to reduce the production of certain proteins and genes related to various diseases. Arrowhead collaborates with major pharmaceutical companies like GlaxoSmithKline, Takeda, Amgen, and Sarepta Therapeutics. Founded in 2003, the company is led by CEO Dr. Christopher R. Anzalone and employs 711 people.
Bottom Line
State Street's increased stake in Arrowhead Pharmaceuticals reflects ongoing institutional interest in the biotech sector. Investors keep a close eye on such filings to gauge institutional sentiment, though these reports are backward-looking and may not represent current positions. Arrowhead's recent financials and insider activities, along with analyst updates, provide a comprehensive view of the company's current market standing.
Related Filing Alerts
Source: State Street's 13F filing on $ARWR (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: State Street 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts